{"resourceType":"ValueSet","id":"2.16.840.1.113883.3.1444.3.226","meta":{"versionId":"6","lastUpdated":"2023-04-25T01:01:01.000-04:00","profile":["http://hl7.org/fhir/StructureDefinition/shareablevalueset","http://hl7.org/fhir/us/cqfmeasures/StructureDefinition/publishable-valueset-cqfm"]},"extension":[{"url":"http://hl7.org/fhir/StructureDefinition/valueset-author","valueString":"American Society of Clinical Oncology Author"},{"url":"http://hl7.org/fhir/StructureDefinition/resource-lastReviewDate","valueDate":"2023-04-25"},{"url":"http://hl7.org/fhir/StructureDefinition/valueset-effectiveDate","valueDate":"2023-04-25"}],"url":"http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.226","identifier":[{"system":"urn:ietf:rfc:3986","value":"urn:oid:2.16.840.1.113883.3.1444.3.226"}],"version":"20230425","name":"LAG3Inhibitor","title":"LAG 3 Inhibitor","status":"active","date":"2023-04-25T01:01:01-04:00","publisher":"American Society of Clinical Oncology Steward","jurisdiction":[{"coding":[{"system":"urn:iso:std:iso:3166","code":"US"}]}],"purpose":"(Clinical Focus: The purpose of this value set is to represent concepts of medication LAG 3 Inhibitor.),(Data Element Scope: This value set may use a model element related to Medication.),(Inclusion Criteria: Includes concepts that represent a medication LAG 3 Inhibitor; generic; prescribable; injectable.),(Exclusion Criteria: Excludes concepts that represent non-prescribable branded drugs, components or ingredients.)","compose":{"include":[{"system":"http://www.nlm.nih.gov/research/umls/rxnorm","concept":[{"code":"2596778","display":"20 ML nivolumab-rmbw 12 MG/ML / relatlimab-rmbw 4 MG/ML Injection"}]}]},"expansion":{"identifier":"urn:uuid:3501697f-9a02-4996-9227-0d958a3de4de","timestamp":"2023-12-11T01:19:55-05:00","total":1,"contains":[{"system":"http://www.nlm.nih.gov/research/umls/rxnorm","version":"11062023","code":"2596778","display":"20 ML nivolumab-rmbw 12 MG/ML / relatlimab-rmbw 4 MG/ML Injection"}]}}